Evidence-Based Treatment of ADHD: Pharmacotherapy and Psychosocial Interventions in Current Clinical Guidelines
DOI:
https://doi.org/10.12775/JEHS.2026.88.69287Keywords
ADHD, treatment, pharmacotherapy, cognitive behavioral therapyAbstract
Background. Attention-deficit/hyperactivity disorder (ADHD) is a condition that affects how a person focuses, regulates behavior, and manages impulses. As a result, individuals with ADHD often experience difficulties in everyday life, including at school, at work, and in social relationships. It is characterized by persistent attention deficit, hyperactivity, and impulsivity.
Aim. This literature review evaluates current treatments for ADHD, including both medication and non-medication options, and discusses their effectiveness.
Materials and Methods. This review summarizes current evidence on medication and psychosocial treatments for attention-deficit/hyperactivity disorder (ADHD). The review included original studies and reviews from the Cochrane, PubMed, and Google Scholar databases. The article selection process ended in February 2026.
Results. Medicines that stimulate the brain are the best treatment for ADHD for people of all ages. Non-stimulant medications show moderate effectiveness and may be particularly useful in patients with contraindications to stimulants or comorbid conditions. Pharmacotherapy tends to produce larger effect sizes in children than in adults, although it is effective in both populations.
Conclusions. The current evidence shows that a multimodal approach is the best way to treat ADHD. Stimulants are still the best type of drug for this, but doctors need to plan treatments for each patient that take into account their mental and social well-being, any other health problems, their age, and how well they can handle the medication to ensure the best possible care.
References
[1]-Substance Abuse and Mental Health Services Administration. DSM-5 Changes: Implications for Child Serious Emotional Disturbance [Internet]. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2016 Jun. Table 7, DSM-IV to DSM-5 Attention-Deficit/Hyperactivity Disorder Comparison. Available from: https://www.ncbi.nlm.nih.gov/books/NBK519712/table/ch3.t3/
[2]-Salari N, Ghasemi H, Abdoli N, Rahmani A, Shiri MH, Hashemian AH, Akbari H, Mohammadi M. The global prevalence of ADHD in children and adolescents: a systematic review and meta-analysis. Ital J Pediatr. 2023 Apr 20;49(1):48. doi: 10.1186/s13052-023-01456-1. PMID: 37081447; PMCID: PMC10120242.
[3]- Song P, Zha M, Yang Q, Zhang Y, Li X, Rudan I; Global Health Epidemiology Reference Group (GHERG). The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysis. J Glob Health. 2021 Feb 11;11:04009. doi: 10.7189/jogh.11.04009. PMID: 33692893; PMCID: PMC7916320.
[4]-Jangmo A, Kuja-Halkola R, Pérez-Vigil A, Almqvist C, Bulik CM, D'Onofrio B, Lichtenstein P, Ahnemark E, Werner-Kiechle T, Larsson H. Attention-deficit/hyperactivity disorder and occupational outcomes: The role of educational attainment, comorbid developmental disorders, and intellectual disability. PLoS One. 2021 Mar 17;16(3):e0247724. doi: 10.1371/journal.pone.0247724. PMID: 33730071; PMCID: PMC7968636.
[5]- Sciberras E, Streatfeild J, Ceccato T, Pezzullo L, Scott JG, Middeldorp CM, Hutchins P, Paterson R, Bellgrove MA, Coghill D. Social and Economic Costs of Attention-Deficit/Hyperactivity Disorder Across the Lifespan. J Atten Disord. 2022 Jan;26(1):72-87. doi: 10.1177/1087054720961828. Epub 2020 Oct 13. PMID: 33047627.
[6]- Banaschewski T, Becker K, Döpfner M, Holtmann M, Rösler M, Romanos M. Attention-Deficit/Hyperactivity Disorder. Dtsch Arztebl Int. 2017 Mar 3;114(9):149-159. doi: 10.3238/arztebl.2017.0149. PMID: 28351467; PMCID: PMC5378980.
[7]- DSM-V (2013). Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). American Psychiatric Publishing.
[8]- Bogdańska-Chomczyk E, Majewski MK, Kozłowska A. ADHD in Adulthood: Clinical Presentation, Comorbidities, and Treatment Perspectives. International Journal of Molecular Sciences. 2025; 26(22):11020. https://doi.org/10.3390/ijms262211020
[9]- Njardvik U, Wergeland GJ, Riise EN, Hannesdottir DK, Öst LG. Psychiatric comorbidity in children and adolescents with ADHD: A systematic review and meta-analysis. Clin Psychol Rev. 2025 Jun;118:102571. doi: 10.1016/j.cpr.2025.102571. Epub 2025 Mar 26. PMID: 40245462.
[10,15,32]- Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, Atkinson LZ, Tessari L, Banaschewski T, Coghill D, Hollis C, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen HC, Shokraneh F, Xia J, Cipriani A. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018 Sep;5(9):727-738. doi: 10.1016/S2215-0366(18)30269-4. Epub 2018 Aug 7. PMID: 30097390; PMCID: PMC6109107.
[11,13]- Faraone SV. The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev. 2018 Apr;87:255-270. doi: 10.1016/j.neubiorev.2018.02.001. Epub 2018 Feb 8. PMID: 29428394; PMCID: PMC8063758.
[12]-Wilens TE. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2008 Jun;28(3 Suppl 2):S46-53. doi: 10.1097/JCP.0b013e318173312f. PMID: 18480677.
[14]- Castells X, Blanco-Silvente L, Cunill R. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2018 Aug 9;8(8):CD007813. doi: 10.1002/14651858.CD007813.pub3. PMID: 30091808; PMCID: PMC6513464.
[16]- Grcevich S, Rowane WA, Marcellino B, Sullivan-Hurst S. Retrospective comparison of Adderall and methylphenidate in the treatment of attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2001 Spring;11(1):35-41. doi: 10.1089/104454601750143401. PMID: 11322743.
[17]- Peterson BS, Trampush J, Maglione M, Bolshakova M, Rozelle M, Miles J, Pakdaman S, Brown M, Yagyu S, Motala A, Hempel S. Treatments for ADHD in Children and Adolescents: A Systematic Review. Pediatrics. 2024 Apr 1;153(4):e2024065787. doi: 10.1542/peds.2024-065787. PMID: 38523592.
[18]- Bieś R, Fojcik J, Warchala A, Trędzbor B, Krysta K, Piekarska-Bugiel K, Krzystanek M. The Risk of Methylphenidate Pharmacotherapy for Adults with ADHD. Pharmaceuticals. 2023; 16(9):1292. https://doi.org/10.3390/ph16091292
[19]- Chiappini S, Gramuglia PD, Mosca A, Cavallotto C, Miuli A, Corkery JM, Guirguis A, Schifano F, Martinotti G. Methylphenidate abuse and misuse in patients affected with a psychiatric disorder and a substance use disorder: a systematic review. Front Psychiatry. 2024 Nov 18;15:1508732. doi: 10.3389/fpsyt.2024.1508732. PMID: 39624511; PMCID: PMC11609911.
[20]-Żełabowski K, Petrov W, Ślebioda D, Rusinek M, Biedka K, Błaszczyk K, Wesołowski M, Wojtysiak K, Sroka M, Ratka Z, Ilski I, Chłopaś-Konowałek A. Holistic Management of Adult ADHD with a History of Addiction: Emphasis on Low-Addiction-Risk Psychopharmacotherapy. J Clin Med. 2025 Sep 14;14(18):6470. doi: 10.3390/jcm14186470. PMID: 41010674; PMCID: PMC12470561.
[21]- Fu D, Wu DD, Guo HL, Hu YH, Xia Y, Ji X, Fang WR, Li YM, Xu J, Chen F, Liu QQ. The Mechanism, Clinical Efficacy, Safety, and Dosage Regimen of Atomoxetine for ADHD Therapy in Children: A Narrative Review. Front Psychiatry. 2022 Feb 9;12:780921. doi: 10.3389/fpsyt.2021.780921. PMID: 35222104; PMCID: PMC8863678.
[22]- Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. PMID: 19445548.
[23]- Martins PLB, Torquato GCP, Dias GAPF, Leite IB, Gaspar TM, Pinto JP, Macedo DS. Effectiveness of pharmacological interventions for managing ADHD symptoms in individuals with autism spectrum disorder: A systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2024 Aug 30;134:111089. doi: 10.1016/j.pnpbp.2024.111089. Epub 2024 Jul 14. PMID: 39004333.
[24]- Fedder D, Patel H, Saadabadi A. Atomoxetine. [Updated 2023 Mar 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK493234/?utm_source=chatgpt.com
[25]- Huecker MR, Smiley A, Saadabadi A. Bupropion. [Updated 2024 Sep 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470212/?utm_source=chatgpt.com
[26]- Wilens TE, Spencer TJ, Biederman J, Girard K, Doyle R, Prince J, Polisner D, Solhkhah R, Comeau S, Monuteaux MC, Parekh A. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry. 2001 Feb;158(2):282-8. doi: 10.1176/appi.ajp.158.2.282. PMID: 11156812.
[27]- Verbeeck W, Bekkering GE, Van den Noortgate W, Kramers C. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2017 Oct 2;10(10):CD009504. doi: 10.1002/14651858.CD009504.pub2. PMID: 28965364; PMCID: PMC6485546.
[28]- Davidson J. Seizures and bupropion: a review. J Clin Psychiatry. 1989 Jul;50(7):256-61. PMID: 2500425.
[29]- Alamo C, López-Muñoz F, Sánchez-García J. Mechanism of action of guanfacine: a postsynaptic differential approach to the treatment of attention deficit hyperactivity disorder (adhd). Actas Esp Psiquiatr. 2016 May;44(3):107-12. Epub 2016 May 1. PMID: 27254403.
[30]- Yu S, Shen S, Tao M. Guanfacine for the Treatment of Attention-Deficit Hyperactivity Disorder: An Updated Systematic Review and Meta-Analysis. J Child Adolesc Psychopharmacol. 2023 Mar;33(2):40-50. doi: 10.1089/cap.2022.0038. PMID: 36944092.
[31]- Yu S, Shen S, Tao M. Guanfacine for the Treatment of Attention-Deficit Hyperactivity Disorder: An Updated Systematic Review and Meta-Analysis. J Child Adolesc Psychopharmacol. 2023 Mar;33(2):40-50. doi: 10.1089/cap.2022.0038. PMID: 36944092.
[33]- Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry. 2009 Sep;48(9):884-893. doi: 10.1097/CHI.0b013e3181b26e9f. PMID: 19625978; PMCID: PMC3943246.
[34]- Fu X, Wu W, Wu Y, Liu X, Liang W, Wu R, Li Y. Adult ADHD and comorbid anxiety and depressive disorders: a review of etiology and treatment. Front Psychiatry. 2025 Jun 6;16:1597559. doi: 10.3389/fpsyt.2025.1597559. PMID: 40547117; PMCID: PMC12179154.
[35]- Adler LA, Wilens T, Zhang S, Dittmann RW, D'Souza DN, Schuh L, Durell TM. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis. Clin Ther. 2012 Feb;34(2):363-73. doi: 10.1016/j.clinthera.2011.12.015. Epub 2012 Jan 27. PMID: 22285724.
[36]- Khajehpiri Z, Mahmoudi-Gharaei J, Faghihi T, Karimzadeh I, Khalili H, Mohammadi M. Adverse reactions of Methylphenidate in children with attention deficit-hyperactivity disorder: Report from a referral center. J Res Pharm Pract. 2014 Oct;3(4):130-6. doi: 10.4103/2279-042X.145389. PMID: 25535621; PMCID: PMC4262859.
[37]- Tripodi B, Carbone MG, Matarese I, Rizzato R, Della Rocca F, De Dominicis F, Callegari C. Effectiveness of Pharmacological Treatments for Adult ADHD on Psychiatric Comorbidity: A Systematic Review. Journal of Clinical Medicine. 2025; 14(24):8848. https://doi.org/10.3390/jcm14248848
[38]- Yang Liu, Feilong Zhu, Yueyong Yu, Yiqi Song, Hao Luo, Baohua Xu, Shengqi Lin, Zhitong Ha, Dongqing Kuang, Yongtao Xie, Zhexue Chen, Yuanchun Ren, A meta-analysis of the intervention effect of cognitive behavioral therapy on adult ADHD, Journal of Affective Disorders, Volume 399, 2026, 121107, ISSN 0165-0327, https://doi.org/10.1016/j.jad.2025.121107.
[39]- Zhang Z, Gu WJ, Wei Y, Wu S, Wang C. Dialectical behavioral therapy for adult attention deficit/hyperactivity disorder: A meta-analysis of randomized controlled trials. Psychiatry Res. 2025 Sep;351:116551. doi: 10.1016/j.psychres.2025.116551. Epub 2025 May 21. PMID: 40513141.
[40]- A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry. 1999 Dec;56(12):1073-86. doi: 10.1001/archpsyc.56.12.1073. PMID: 10591283.
[41]-PETER S. JENSEN, L. EUGENE ARNOLD, JAMES M. SWANSON, BENEDETTO VITIELLO, HOWARD B. ABIKOFF, LAURENCE L. GREENHILL, LILY HECHTMAN, STEPHEN P. HINSHAW, WILLIAM E. PELHAM, KAREN C. WELLS, C. KEITH CONNERS, GLEN R. ELLIOTT, JEFFERY N. EPSTEIN, BETSY HOZA, JOHN S. MARCH, BROOKE S.G. MOLINA, JEFFREY H. NEWCORN, JOANNE B. SEVERE, TIMOTHY WIGAL, ROBERT D. GIBBONS, KWAN HUR, 3-Year Follow-up of the NIMH MTA Study, Journal of the American Academy of Child & Adolescent Psychiatry, Volume 46, Issue 8, 2007, Pages 989-1002, ISSN 0890-8567, https://doi.org/10.1097/CHI.0b013e3180686d48.
[42]-Tycho J. Dekkers, Rianne Hornstra, Saskia van der Oord, Marjolein Luman, Pieter J. Hoekstra, Annabeth P. Groenman, Barbara J. van den Hoofdakker, Meta-analysis: Which Components of Parent Training Work for Children With Attention-Deficit/Hyperactivity Disorder?, Journal of the American Academy of Child & Adolescent Psychiatry, Volume 61, Issue 4, 2022, Pages 478-494, ISSN 0890-8567, https://doi.org/10.1016/j.jaac.2021.06.015.
[43]-Hafiz Ahmet B, Bıkmazer A, Gormez V. CBT, parent training, and combined approaches for children with ADHD: A randomized study. Psychol Psychother. 2026 Mar;99(1):149-165. doi: 10.1111/papt.70011. Epub 2025 Sep 4. PMID: 40908762.
[44]-Storebø OJ, Elmose Andersen M, Skoog M, Joost Hansen S, Simonsen E, Pedersen N, Tendal B, Callesen HE, Faltinsen E, Gluud C. Social skills training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years. Cochrane Database of Systematic Reviews 2019, Issue 6. Art. No.: CD008223. DOI: 10.1002/14651858.CD008223.pub3.
[45]- Hunter C, Smith C, Davies E, Dyall SC, Gow RV. A closer look at the role of nutrition in children and adults with ADHD and neurodivergence. Front Nutr. 2025 Jul 30;12:1586925. doi: 10.3389/fnut.2025.1586925. PMID: 40808843; PMCID: PMC12343232.
[46]- Abdullah M, Jowett B, Whittaker PJ, Patterson L. The effectiveness of omega-3 supplementation in reducing ADHD associated symptoms in children as measured by the Conners' rating scales: A systematic review of randomized controlled trials. J Psychiatr Res. 2019 Mar;110:64-73. doi: 10.1016/j.jpsychires.2018.12.002. Epub 2018 Dec 12. PMID: 30594823.
[47]- Leung BMY, Srikanth P, Robinette L, Bruton AM, Tost G, Hatsu I, Arnold LE, Johnstone JM. Micronutrients for ADHD in youth (MADDY) study: comparison of results from RCT and open label extension. Eur Child Adolesc Psychiatry. 2024 May;33(5):1355-1367. doi: 10.1007/s00787-023-02236-2. Epub 2023 Jun 8. PMID: 37291464; PMCID: PMC10703999.
[48]- Abd El Baaki, O.M., Abd El Hamid, E.R., Zaki, S.T. et al. Diet modification impact on ADHD outcome. Bull Natl Res Cent 45, 15 (2021). https://doi.org/10.1186/s42269-020-00466-x
[49]- Arnold LE, Lofthouse N, Hurt E. Artificial food colors and attention-deficit/hyperactivity symptoms: conclusions to dye for. Neurotherapeutics. 2012 Jul;9(3):599-609. doi: 10.1007/s13311-012-0133-x. PMID: 22864801; PMCID: PMC3441937.
[50]- Nigg JT, Lewis K, Edinger T, Falk M. Meta-analysis of attention-deficit/hyperactivity disorder or attention-deficit/hyperactivity disorder symptoms, restriction diet, and synthetic food color additives. J Am Acad Child Adolesc Psychiatry. 2012 Jan;51(1):86-97.e8. doi: 10.1016/j.jaac.2011.10.015. PMID: 22176942; PMCID: PMC4321798.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Joanna Madoń, Marta Czechowicz, Patryk Gadziński

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 6
Number of citations: 0